-
2025-523975-48-00
5
2026-05-08
Obesity
-
2024-520443-16-00
5
2026-05-04
Overweight or obesity, and obstructive sleep apnoea treated with posit
-
2024-520442-36-00
5
2026-04-30
Overweight or obesity, and obstructive sleep apnoea not treated with p
-
2025-523914-10-00
6
2026-04-30
Critical illness
-
2025-524366-21-00
5
2026-04-29
treatment-naive Chronic Lymphocytic Leukemia
-
2025-522567-15-00
5
2026-04-28
Plaque Psoriasis
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2025-523804-62-00
5
2026-04-28
Obesity
-
2024-520014-22-00
5
2026-04-22
Locally advanced/metastatic urothelial carcinoma
-
2025-524542-10-00
4
2026-04-14
Endometrial cancer
-
2025-522583-32-00
5
2026-04-13
Cold-Induced Urticaria and Symptomatic Dermographism
-
2025-522387-32-00
5
2026-04-10
Uveal Melanoma
-
2025-523342-27-00
4
2026-04-10
Alopecia areata
-
2025-522402-21-00
1
2026-03-27
Advanced solid tumors (cutaneous melanoma, mucosal melanoma, cutaneous
-
2025-522544-40-00
5
2026-03-27
Hereditary transthyretin-mediated amyloidosis with polyneuropathy
-
2025-522046-42-00
5
2026-03-24
Colonic disease
-
2025-521762-99-00
5
2026-03-09
acute ischemic stroke
-
2025-521642-14-00
4
2026-03-05
Multiple System Atrophy
-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2023-509860-47-00
4
2026-02-20
Ductal carcinoma in situ
-
2025-521805-41-00
5
2026-02-18
Patients with HER2-positive, locally advanced or metastatic breast can
-
2024-516356-18-00
5
2026-02-17
Atherosclerotic cardiovascular disease (ASCVD)
-
2024-516966-12-00
4
2026-02-13
Alzheimer’s disease
-
2025-521636-10-00
4
2026-02-04
Progressive Forms of Multiple Sclerosis (PMS)